Imagen por defecto


DAA use decreases risk for cardiovascular events in patients with advanced fibrosis, HCV

LONDON — Direct-acting antiviral treatment correlated with a decreased risk for cardiovascular outcomes among patients with hepatitis C virus and advanced fibrosis but an increased risk for arrhythmias and conduction disorders.
“Several studies have revealed that hepatitis C virus can induce chronic inflammation and immune dysregulation, and this immune dysregulation and chronic inflammation explained the development of extrahepatic manifestations in chronic hepatitis C patients, including cardiovascular disease,” Laurent Lam, MD, a physician and doctoral researcher at the

NAFLD, alcohol-associated liver disease spurs rise in global liver cancer deaths

LONDON — Nonalcoholic fatty liver disease and alcohol-associated liver disease are among the main contributors of increased mortality related to chronic liver disease and liver cancer burden, according to research.
“Although viral hepatitis B and C and alcohol liver disease have historically been the drivers of burden of chronic liver disease and liver cancer, NAFLD and nonalcoholic steatohepatitis have increasingly become more prominent,” Zobair Younossi, MD, MPH, president of Inova Health System Center for Liver Diseases, said. “The most recent meta-analysis suggests

CV complications of COVID-19 vary widely; patients with HF at high risk

PHILADELPHIA — The CV complications of COVID-19 are wide-ranging, and the consequences can be especially serious in patients with HF, a speaker said at the Heart in Diabetes CME conference.
The presentation by Lee R. Goldberg, MD, MPH, FACC, section chief of advanced cardiac failure and heart transplant, vice chair for medicine informatics and professor of medicine at the University of Pennsylvania, covered a number of topics related to cardiac complications of COVID-19.

Patients with preexisting HF can have it exacerbated after getting COVID-19, Goldberg said. COVID-19 can also confer

Low-carbohydrate, high-fat diet reduced fatty liver, improved type 2 diabetes control

LONDON — A low-carbohydrate, high-fat diet significantly improved nonalcoholic fatty liver disease activity score and HbA1c more than a high-carbohydrate, low-fat diet in people with type 2 diabetes mellitus, according to a researcher here.
“If you have fat in the liver, you will benefit from eating fat,” Camilla Dalby Hansen, MD, from Odense University Hospital in Denmark, told attendees at the International Liver Congress. “This is the conclusion to our research study, which is the foremost extensive research study done on this particular diet in patients with type 2

In type 2 diabetes, ‘something brain-friendly’ about GLP-1 receptor agonists

PHILADELPHIA — Diabetes independently increases risk for cognitive decline, yet data from several large trials suggest GLP-1 receptor agonists hold significant promise to mitigate risk for dementia-related events, according to a speaker.
“In addition to age and other risk factors, diabetes is a risk factor for cognitive decline, as is the degree of hyperglycemia,” Hertzel C. Gerstein, MD, MSc, FRCPC, professor and population health institute chair in diabetes research at McMaster University and Hamilton Health Sciences in Ontario, Canada, told Healio before speaking at the

Female prisons ‘main reservoir’ for hepatitis C, key target for elimination initiatives

LONDON — A high intensity test and treat initiative for hepatitis C elimination in England proved to be beneficial for testing and treating incarcerated individuals, according to results at the International Liver Congress.
“The [National Health Service] hepatitis C elimination program is working toward a shared goal of eliminating hepatitis C as a public health issue, in line with the proposed WHO goal, by 2030,” Beatrice Emmanouil, PhD, from NHS England, told attendees. “Prison populations are known to have a higher rate of people living with a hepatitis C infection

FDA grants fast track designation to PDS0101 for head and neck cancer subset

The FDA granted fast track designation to PDS0101 for treatment of certain patients with head and neck cancer.
The designation applies to use of the agent in combination with pembrolizumab (Keytruda, Merck) by patients with recurrent or metastatic HPV16-positive disease.
PDS0101 (PDS Biotechnology Corporation) is a T-cell HPV-specific immunotherapy delivered subcutaneously.
Prior studies have demonstrated its potential to stimulate high levels of HPV16-specific CD8-positive and CD4-positive T cells by activating multiple immune pathways, according to a PDS Biotech-issued press release. These T

HOPCo partners with Future Health Works, acquires patient tracking platform

Healthcare Outcomes Performance Company has announced the acquisition of several patient engagement and outcome tracking platforms from Future Health Works, according to a press release.
Healthcare Outcomes Performance Company (HOPCo) will acquire software from Future Health Works (FHW), including and myrecovery, along with a remote patient monitoring and patient feedback platform, artificial intelligence platform, computer vision platform and patented motion capture technology.
“The FHW platforms and their AI capabilities combined with HOPCo’s outcomes management